IndustriesHealth

Products 51 to 60 of 63

SYN-004 (RIBAXAMASE) by Synthetic Biologics
Biotech components: Microbe
Business models: B2B
Country of production: USA
Country of distribution: USA
Intended consumer: Commercial
Date added: 2018/08/30 11:49 (6 years ago)
Date last modified: 2018/08/30 11:49 (6 years ago)
Known funding amount: 12,467,000 USD
Funding types: Shareholder Investment
Industry: Health
Market status: Under Development
Organization type(s): Public Company
Product categories: Medical Treatment
Production process: Closed Production
Source: SynBio Database
Trading symbol: SYN (NYSEMKT)
Value chain stage: Finished Product
SYN-005 by Synthetic Biologics + Intrexon
Biotech components: Molecule
Business models: B2B
Country of production: USA
Country of distribution: USA
Intended consumer: Commercial
Date added: 2018/08/30 11:49 (6 years ago)
Date last modified: 2018/10/01 09:27 (6 years ago)
Known funding amount: 24,800,000 USD
Funding types: Shareholder Investment
Industry: Health
Market status: Under Development
Organization type(s): Public Company
Product categories: Medical Treatment
Production process: Closed Production
Source: Web search
Trading symbol: SYN (NYSEMKT)
Value chain stage: Finished Product
SYNB1020 by Synlogic
Biotech components: Microbe
Business models: B2C
Country of production: USA
Country of distribution: USA
Intended consumer: Consumer + Commercial
Date added: 2018/08/30 11:49 (6 years ago)
Date last modified: 2018/08/30 11:49 (6 years ago)
Known funding amount: 125,800,000 USD
Funding types: Shareholder Investment
Industry: Health
Market status: Under Development
Organization type(s): Public Company
Product categories: Medical Treatment
Production process: Closed Production
Source: Web search
Trading symbol: SYBX (NASDAQ)
Value chain stage: Finished Product
SYNB1618 by Synlogic
Biotech components: Microbe
Business models: B2C
Country of production: USA
Country of distribution: USA
Intended consumer: Commercial + Consumer
Date added: 2018/08/30 11:49 (6 years ago)
Date last modified: 2018/10/08 14:53 (6 years ago)
Known funding amount: 125,800,000 USD
Funding types: Shareholder Investment
Industry: Health
Market status: Under Development
Organization type(s): Public Company
Product categories: Medical Treatment
Production process: Closed Production
Source: Web search
Trading symbol: SYBX (NASDAQ)
Value chain stage: Finished Product
Synbio Lantibiotics by University of Groningen
Biotech components: Bacteria
Business models: B2B
Country of production: USA
Country of distribution: N/A
Intended consumer: N/A
Date added: 2018/08/30 11:49 (6 years ago)
Date last modified: 2018/08/30 11:49 (6 years ago)
Known funding amount: N/A
Funding types: Public Funding
Industry: Health
Market status: More information needed + Under Development
Organization type(s): University
Product categories: Medical Treatment
Production process: Closed Production
Source: SynBio Database
Trading symbol: N/A
Value chain stage: Input
Synthorin™ Protein by Synthorx + Scripps Research Institute
Biotech components: Molecule
Business models: B2B
Country of production: USA
Country of distribution: USA
Intended consumer: Research
Date added: 2018/08/30 11:49 (6 years ago)
Date last modified: 2018/08/30 11:49 (6 years ago)
Known funding amount: 79,000,000 USD
Funding types: Venture Capital
Industry: Health
Market status: Under Development
Organization type(s): Private Company
Product categories: Medical Treatment
Production process: Open Release
Source: SynBio Database
Trading symbol: N/A
Value chain stage: Finished Product
TALEN by Cellectis
Biotech components: Molecule
Business models: B2B
Country of production: USA + France
Country of distribution: USA + France
Intended consumer: Research
Date added: 2018/08/30 11:49 (6 years ago)
Date last modified: 2018/08/30 11:49 (6 years ago)
Known funding amount: 17,400,000 EUR
Funding types: Shareholder Investment
Industry: Health + Multipurpose
Market status: On the market
Organization type(s): Public Company
Product categories: Research
Production process: Closed Production
Source: Web search
Trading symbol: CLLS, ALCLS (NASDAQ, EPA)
Value chain stage: Platform
Biotech components: Bacteria
Business models: N/A
Country of production: USA
Country of distribution: USA
Intended consumer: Commercial
Date added: 2018/08/30 11:49 (6 years ago)
Date last modified: 2018/09/14 10:43 (6 years ago)
Known funding amount: N/A
Funding types: Foundation + University
Industry: Health
Market status: Early Stage Concept
Organization type(s): University
Product categories: Medical Treatment
Production process: Closed Production
Source: SynBio Database
Trading symbol: N/A
Value chain stage: Input
Vitamin D2 by Nucelis
Biotech components: Plant
Business models: B2B + B2C
Country of production: USA
Country of distribution: USA
Intended consumer: Commercial
Date added: 2018/08/30 11:49 (6 years ago)
Date last modified: 2018/08/30 11:49 (6 years ago)
Known funding amount: N/A
Funding types: N/A
Industry: Health
Market status: On the market
Organization type(s): Private Company
Product categories: Personal Care (Ingested) + Food
Production process: Open Release
Source: N/A
Trading symbol: N/A
Value chain stage: Finished Product
Biotech components: Plant
Business models: N/A
Country of production: USA
Country of distribution: USA
Intended consumer: Commercial
Date added: 2018/08/30 11:49 (6 years ago)
Date last modified: 2018/08/30 11:49 (6 years ago)
Known funding amount: N/A
Funding types: N/A
Industry: Health
Market status: On the market
Organization type(s): Private Company
Product categories: Food
Production process: Open Release
Source: N/A
Trading symbol: N/A
Value chain stage: Finished Product